Avalo Therapeutics, Inc.
NASDAQ: AVTX0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Capital Market
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Garry A. Neil
- Employees
- 23
- Headquarters
- Rockville, United States
- IPO year
- 2015
- Market cap
- $205.1M
- Website
- https://www.avalotx.com
Loading AVTX…
Loading profile data…Frequently asked questions about AVTX
What does Avalo Therapeutics, Inc. (AVTX) do?
Avalo Therapeutics, Inc. is a precision medicine company in the clinical development phase, dedicated to identifying, advancing, and marketing specialized treatments for patients experiencing critical unmet medical needs across the fields of immunology, immuno-oncology, and rare genetic disorders. Among its key pipeline assets is AVTX-002, a ful...
Where does AVTX trade?
Avalo Therapeutics, Inc. (AVTX) trades on the NASDAQ Capital Market.
What sector is AVTX in?
Avalo Therapeutics, Inc. (AVTX) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Avalo Therapeutics, Inc.?
Garry A. Neil is the chief executive officer of Avalo Therapeutics, Inc. (AVTX).
Where is Avalo Therapeutics, Inc. headquartered?
Avalo Therapeutics, Inc. is headquartered in United States.
Does AVTX pay a dividend?
Avalo Therapeutics, Inc. (AVTX) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did AVTX go public?
Avalo Therapeutics, Inc. (AVTX) completed its initial public offering in 2015.